You just read:

Actinium's Late Breaking Oral Presentation at 2019 TCT Meetings Reports New Data on Donor Chimerism Indicating Deep Engraftment in All Iomab-B Treated Patients in the Pivotal Phase 3 SIERRA Trial

News provided by

Actinium Pharmaceuticals, Inc.

Feb 25, 2019, 08:00 ET